A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
- Conditions
- Psychotic DepressionSevere Major Depression With Psychotic FeaturesPsychosis
- Interventions
- Drug: placebo
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 292
- Registration Number
- NCT00637494
- Locations
- ๐บ๐ธ
Inquest Clinical Group/ Global Research Associates, Hope Mills, North Carolina, United States
๐บ๐ธCollaborative Neuroscience Network, Inc., Garden Grove, California, United States
๐บ๐ธBreakthrough Clinical Trials, San Bernardino, California, United States
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00569582
- Locations
- ๐บ๐ธ
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
๐บ๐ธUniversity of Mississippi Medical Center, Jackson, Mississippi, United States
๐บ๐ธThe Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
- Conditions
- Weight-Gain Prevention
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2008-09-19
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00455442
- Locations
- ๐ฎ๐ณ
St. John's Medical College, Bangalore, India
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 87
- Registration Number
- NCT00208156
- Locations
- ๐บ๐ธ
Claghorn-Lesem Research Clinic, Bellaire, Texas, United States
๐บ๐ธNew Jersey Medical School - UMDNJ, Newark, New Jersey, United States
๐บ๐ธCnri, Llc, San Diego, California, United States
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 247
- Registration Number
- NCT00146523
- Locations
- ๐ญ๐ท
Dubravka Kocijan-Hercigonja M.D., Zagreb, Croatia
๐ญ๐ทVera Folnegovic-Smalc M.D./Ph.D., Zagreb, Croatia
๐ท๐ดMihai Dumitru Gheorge, Bucharest, Romania
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Major Depressive DisorderPsychotic Disorders
- Interventions
- Drug: matching placebo
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 257
- Registration Number
- NCT00130676
- Locations
- ๐บ๐ธ
NMDNJ, Newark, New Jersey, United States
๐บ๐ธCNRI-LA, Pico Rivera, California, United States
๐บ๐ธNeurobehavioral Research Company, Lawrence, New York, United States
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Major Depressive DisorderPsychotic Disorders
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT00128505
- Locations
- ๐ง๐ฌ
Svetlozar H Haralanov Ph.D., Sofia, Bulgaria
๐ญ๐ทVera Folnegovic-Smalc M.D/Ph.D, Zagreb, Croatia
๐ง๐ฌVihra Milanova M.D., Sofia, Bulgaria
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Major Depressive DisorderPsychotic Disorders
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 443
- Registration Number
- NCT00128479
- Locations
- ๐บ๐ธ
Saint Vincent Catholic Medical Centers of New York, Staten Island, New York, United States
๐บ๐ธCNS Research Institute (CRI), Philadelphia, Pennsylvania, United States
๐บ๐ธHarmony Research, Johnson City, Tennessee, United States
Mifepristone as Adjunctive Therapy in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2005-03-07
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 160
- Registration Number
- NCT00105105
- Locations
- ๐บ๐ธ
Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States
๐บ๐ธClinical Physiology Associates, Ft. Myers, Florida, United States
๐บ๐ธInternational Clinical Research Associates, Virginia Beach, Virginia, United States